UK Researchers Restore Sleep in Alzheimer's Mice by Targeting Immune Cells, Not Plaques
University of Kentucky researchers found that removing 87% of brain immune cells in mice with Alzheimer's-like pathology restored over two hours of daily sleep without reducing amyloid plaques. The study identifies microglia-driven inflammation, not plaque accumulation itself, as the primary cause of sleep disruption. This suggests new therapeutic targets for improving sleep and potentially slowing disease progression.
Key points
- Mice with Alzheimer's-like brain changes regained more than two hours of sleep per day after microglia depletion.
- Sleep improvement occurred despite the continued presence of amyloid plaques, challenging the assumption that plaque removal is necessary for sleep restoration.
- Microglia, the brain's immune cells, trigger excessive inflammation when detecting plaques, which disrupts deep, restorative non-rapid eye movement (NREM) sleep.
- Sleep disruption in Alzheimer's models reached a ceiling early in the disease, meaning additional plaque buildup did not worsen sleep loss proportionally.
- The team is now testing existing drugs like Metformin and Stiripentol to calm microglial activity rather than eliminating the cells entirely.
Background
This finding aligns with recent shifts in Alzheimer's research away from the amyloid hypothesis toward systemic immune and vascular triggers. Earlier studies have linked peripheral immune activation and vascular damage to tau-related brain damage, while other research highlights how sleep quality affects brain waste clearance. The current study adds to this by isolating the specific role of microglia in sleep disruption, offering a potential pathway to break the cycle between poor sleep and disease progression.
Why it matters
Identifying microglia as the driver of sleep loss offers a new treatment avenue that does not require removing amyloid plaques. Improved sleep could enhance memory consolidation and brain waste clearance, potentially slowing cognitive decline. Additionally, the discovery of distinct electrical activity patterns may lead to affordable, portable EEG tools for early Alzheimer's screening, particularly benefiting rural areas with limited access to advanced diagnostic imaging.
What to watch
Researchers are investigating whether drugs like Metformin and Stiripentol can modulate microglial metabolism to reduce inflammation without eliminating the cells. Future studies will focus on translating these mouse results to humans and validating EEG patterns as a longitudinal biomarker for early detection and monitoring.
Want the full story? Read the original reporting
Read on Science Daily